Medicine
Monjuvi 200 mg/5 mL powder for injection
Monjuvi 200 mg/5 mL powder for injection is a prescription medicine containing Tafasitamab for intravenous use, marketed by Incyte, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to…
Key facts
- Active ingredient (INN)
- Tafasitamab
- Brand
- Monjuvi
- Strength
- 200 mg/5 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Incyte
- Manufacturer
- Incyte
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FX12 Tafasitamab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 August 2020
- Identifiers
- RxCUI 2387338, 2387343DailyMed set ID ec13ac6b-bfde-4e84-907a-83bd69584d95, 9e0a220b-517f-4c86-b581-ffbab493fb58NDC 73535-208, 50881-013Application BLA761163
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Tafasitamab is a prescription medicine indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma,, among other approved uses. MedsAcross supplies Tafasitamab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TafasitamabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- MONJUVI prescribing information (Incyte) · U.S. National Library of Medicine, DailyMed
- Minjuvi: European public assessment report (EPAR) · European Medicines Agency
Need Monjuvi 200 mg/5 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.